Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

Inclusion criteria: * Written informed consent * Histologically proven, unresectable, evaluable metastatic colorectal cancer * 16 to 20 weeks of first-line therapy with oxaliplatin, and/or irinotecan-based flourorpyrimidine-containing chemotherapy plus Bevacizumab * Patients must have stable disease (or better) during the initial induction chemotherapy with first-line chemotherapy. * No progressive disease at the time of initiation of maintenance therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 * Adequate organ and marrow function * Women of child-bearing potential and men must agree to avoid pregnancy * Patient must start maintenance therapy at least 14 days after the last administered induction chemotherapy but no later than 30 days. Exclusion Criteria * Patients whose tumors have progressed on first-line treatment * Patients with active concurrent malignancy, other than superficial, non-invasive squamous cell carcinoma of the skin or uterine cervix, within the past three years. * Women who are pregnant or lactating * Unstable heart disease * Uncontrolled active infection requiring antibiotics within one week prior to first dose. * Patients with active CNS malignancy. * Persistent protein in the urine * Patients with bowel obstruction or uncontrolled vomiting. * Patients with serious psychiatric or medical conditions that could interfere with treatment.